Sol-Gel Technologies Ltd. SLGL 深 滬
已收盤 05-22 16:00:00 美东时间
76.73
+8.420
+12.33%
華盛通- 最 高76.83
- 今 開69.95
- 成交量 7.68万股
- 最 低 67.21
- 昨 收 68.31
- 總市值 2.51亿
- 52周最高 97.97
- 市盈率 靜 --
- 換手率 2.35%
- 52周最低 6.80
- 委 比 -66.67%
- 總股本 326.90万
- 歷史最高 210.00
- 量 比 3.01
- 振 幅 14.08%
- 歷史最低 3.34
- 每 手 1
- 風險率 26.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during T...
03-25 01:05
BRIEF-Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering
BRIEF-Sol-Gel Technologies Ltd. Announces Pricing Of Oversubscribed Underwritten Offering March 23 (Reuters) - Sol Gel Technologies Ltd SLGL.O : SOL-GEL TECHNOLOGIES LTD. ANNOUNCES PRICING OF OVERSUBSCRIBED UNDERWRITTEN OFFERING SOL GEL TECHNOLOGIES LTD - SOL-GEL TECHNOLOGIES PRICES 459,112 SHARES A
03-24 09:39
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
Sol-Gel Technologies Ltd. announced the pricing of an underwritten offering of 459,112 ordinary shares at $72.00 per share, raising approximately $33.1 million. The funds will support the development of SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome, with potential applications in high-frequency basal cell carcinoma. The offering includes participation from notable investors and is expected to close on March 25, 2026. Sol-Gel i...
03-24 01:38
Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025
Sol-Gel Technologies Ltd. filed its annual report on Form 20-F for 2025, available on the SEC website and its investor relations site. The company is advancing rare skin disease therapies, including SGT-610, a Phase 3 topical hedgehog inhibitor for Gorlin syndrome patients, and SGT-210, a topical EGFR inhibitor. Sol-Gel also markets FDA-approved dermatology products TWYNEO® and EPSOLAY®.
03-19 12:53
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Shares of pharmaceutical companies are trading lower amid overall market weakne...
03-06 03:56
Ellomay Capital Announces Changes in its Principal Shareholders and Board Composition
Ellomay Capital Ltd. announced that its major shareholders, S. Nechama Investments, Kanir Joint Investments, and Anat Raphael, have sold their 45.9% stake to O.Y. Nofar Energy Ltd. Following the sale, two board members, Anita Leviant and Ehud Gil, resigned immediately, while the chairman, Ben Sheizaf, will step down within 30 days. Two new independent directors, Odelya Ohayon and Gilad Mamlok, were appointed to fill the vacancies, with Mamlok joi...
03-04 21:32
Opaleye Management Inc. reports acquisition of Sol-Gel Technologies common shares
Opaleye Management Inc. reports acquisition of Sol-Gel Technologies common shares Opaleye Management Inc. reported an acquisition of common shares of Sol-Gel Technologies Ltd. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT
02-19 05:06
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers IO Biotech (NASDAQ:IOBT) stock increased by 76.7% to $0.37 during Thur...
01-23 01:05
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
HC Wainwright & Co. Maintains Buy on Sol-Gel Technologies, Raises Price Target to $110
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and raises the price target from $50 to $110.
01-20 19:44
